4.7 Article

Metabolic Fate of Fructose Ingested with and without Glucose in a Mixed Meal

Journal

NUTRIENTS
Volume 6, Issue 7, Pages 2632-2649

Publisher

MDPI
DOI: 10.3390/nu6072632

Keywords

fructose oxidation; gluconeogenesis; glucose production; de novo lipogenesis; hepatic; intestinal; sugar

Funding

  1. Swiss National Foundation for Science [320030-138428, 320030-135782]
  2. Swiss National Science Foundation (SNF) [320030_138428, 320030_135782] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

Ingestion of pure fructose stimulates de novo lipogenesis and gluconeogenesis. This may however not be relevant to typical nutritional situations, where fructose is invariably ingested with glucose. We therefore assessed the metabolic fate of fructose incorporated in a mixed meal without or with glucose in eight healthy volunteers. Each participant was studied over six hours after the ingestion of liquid meals containing either C-13-labelled fructose, unlabeled glucose, lipids and protein (Fr + G) or C-13-labelled fructose, lipids and protein, but without glucose (Fr), or protein and lipids alone (ProLip). After Fr + G, plasma C-13-glucose production accounted for 19.0% +/- 1.5% and (CO2)-C-13 production for 32.2% +/- 1.3% of C-13-fructose carbons. After Fr, C-13-glucose production (26.5% +/- 1.4%) and (CO2)-C-13 production (36.6% +/- 1.9%) were higher (p < 0.05) than with Fr + G. C-13-lactate concentration and very low density lipoprotein VLDL C-13-palmitate concentrations increased to the same extent with Fr + G and Fr, while chylomicron C-13-palmitate tended to increase more with Fr + G. These data indicate that gluconeogenesis, lactic acid production and both intestinal and hepatic de novo lipogenesis contributed to the disposal of fructose carbons ingested together with a mixed meal.Co-ingestion of glucose decreased fructose oxidation and gluconeogenesis and tended to increase C-13-pamitate concentration in gut-derived chylomicrons, but not in hepatic-borne VLDL-triacylglycerol (TG). This trial was approved by clinicaltrial. gov. Identifier is NCT01792089.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available